Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization

Jean-François Rossignol, Matthew C. Bardin, Joshua B. Oaks, B. Gregory Bostick, Kishor N. Vora, Jessica Fulgencio, Dena Mogelnicki, Christian Bréchot, for the Vanguard Study Group
doi: https://doi.org/10.1101/2021.04.19.21255441

Article Information

doi 
https://doi.org/10.1101/2021.04.19.21255441
History 
  • April 20, 2021.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Jean-François Rossignol, MD, PhD1,
  2. Matthew C. Bardin, PharmD, BCPS1,†,
  3. Joshua B. Oaks, MD2,
  4. B. Gregory Bostick, MD3,
  5. Kishor N. Vora, MD4,
  6. Jessica Fulgencio, MBA1,
  7. Dena Mogelnicki1,
  8. Christian Bréchot, MD, PhD1,5,6,
  9. for the Vanguard Study Group*
  1. 1Romark Institute of Medical Research, Tampa, Florida
  2. 2Progressive Clinical Research, Bountiful, Utah
  3. 3Cullman Clinical Trials, Cullman, Alabama
  4. 4Research Integrity, LLC, Owensboro, Kentucky
  5. 5University of South Florida, College of Medicine, Tampa, Florida
  6. 6Global Virus Network
  1. ↵†Corresponding author; email: matthew.bardin{at}romark.com
Back to top
Posted April 20, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization
Jean-François Rossignol, Matthew C. Bardin, Joshua B. Oaks, B. Gregory Bostick, Kishor N. Vora, Jessica Fulgencio, Dena Mogelnicki, Christian Bréchot, for the Vanguard Study Group
medRxiv 2021.04.19.21255441; doi: https://doi.org/10.1101/2021.04.19.21255441
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area